Current and future strategies for combined-modality therapy in pancreatic cancer.
Treatment of pancreatic cancer remains a challenging task that often requires a multidisciplinary approach to confer optimal response and, ideally, maximize survival. A combination of locoregional approaches such as surgery and radiotherapy, along with systemic therapies for eradication of micrometastases, should be considered both for patients who are operative candidates and for those with locally advanced, unresectable disease. How best to combine these modalities in terms of schedule, timing, and choice of agents is a question that continues to be actively investigated. Some of these data are equivocal or conflicting; thus standards of care for combined-modality treatment have not been uniformly accepted to date. This article provides an overview of combined-modality therapy, focusing on the major studies that have guided our current approach to the treatment of pancreatic cancer and examining new strategies that are likely to improve outcomes and survival for patients in the future.
Ko
Andrew H
AH
Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th floor, San Francisco, CA 94115, USA. andrewko@medicine.ucsf.edu
Tempero
Margaret A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D010190:Pancreatic Neoplasms / Q000601:surgery / Q000628:therapy*; D011879:Radiotherapy Dosage